References: Hair growth and hair loss
Ann Plast Surg. 2002 Jan;48(1):1-7; discussion 7-9.
Safety of titanium mesh for orbital reconstruction.
Gear AJ, Lokeh A, Aldridge JH, Migliori MR, Benjamin CI, Schubert W.
Department of Plastic and Hand Surgery, Regions Hospital, 640 Jackson Street, Saint Paul, MN 55101, USA.
During the past several decades, the standard of care for orbital reconstruction after trauma has been autogenous bone grafts. Complications of bone grafts, including donor site morbidities such as scar alopecia and graft resorption with delayed enophthalmos, have inspired an interest in the use of alloplastic substitutes such as titanium. Titanium's role in orbital reconstruction was limited originally to small orbital defects, and as an adjunct to bone grafts. More recently, clinical studies have documented the sole use of titanium mesh to reconstruct large orbital defects. This study sought to document further the safety and efficacy of titanium mesh in reconstructing large orbital defects after facial trauma, with more extensive follow-up compared with previous studies. In the current study, 55 patients with 67 orbital fractures underwent orbital reconstruction with titanium mesh over a 5-year period. Associated fractures were reduced anatomically and fixed rigidly. For the analysis, 44 patients with 56 orbital fractures had adequate follow-up (mean, 44 months). An abscess developed in one patient who received high-dose steroids for 72 hours before reconstruction. She was treated with broad-spectrum intravenous antibiotics and bedside incision and drainage, and did not require removal of the titanium mesh. No patient in the current series required removal of the titanium mesh. A single case of uncorrected enophthalmos was treated with bone grafting rather than mesh revision. Large orbital defects can be reconstructed using titanium mesh with good functional results and minimal risk for infection. This study covered the authors' first 5 years using titanium. They have now used titanium mesh in orbital reconstructions for more than 10 years, without any additional cases of infection.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11773723&dopt=Abstract
Zhonghua Zhong Liu Za Zhi. 2000 Mar;22(2):166-7.
[Clinical observation of palitaxel in the treatment of gynecologic malignant tumors]
[Article in Chinese]
Shao H.
Department of Gynecological Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China.
OBJECTIVE: To observe the therapeutic effect of palitaxel. METHODS: Of 37 cases, 33 were treated when tumor recurrence occurred after surgery or chemotherapy. There were 27 cases with ovarian cancer, 6 with fallopian tube cancer. 3 with cervix cancer, and 1 with endometrium cancer. In all cases, diagnosis was confirmed by histopathology. Palitaxel (135-150 mg/m2) was administered i.v. or i.p. once every three werks in combination with cisplatin (PDD) 60 mg/m2 and cyclophosphamide (CTX) 60 mg/d. Antihistaminics and antiemetic were given prior to palitaxel. The results of treatment were compared with those in 37 cases treated in the some time period with PAC or VBP regimen. RESULTS: The overall median survival time of the control group was 4 months, and 8.5 months in the palitaxel treated group (P < 0.001). The response rate was 18.9% and 48.6% respectively (P < 0.005). The major toxic effects was myelosuppression and alopecia. CONCLUSION: Palitaxel is effective in the treatment of advanced gynecological tumors.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11776651&dopt=Abstract
Zhonghua Zhong Liu Za Zhi. 2000 Mar;22(2):168-9.
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer]
[Article in Chinese]
Li L, Zou Y, Guan X.
Department of Oncology, First Teaching Hospital, Dalian Medical University, Dalian 116011, China.
OBJECTIVE: To observe the response rate and toxic reaction of taxotere in the treatment of advanced NSCLC and breast cancer. METHODS: A total of 24 cases was included in the study. Taxotere 75 mg/m2 i.v. drip for 1 hour; dexamethasone 8 mg bid 24 hour before taxotere, and continued for 3 days. For NSCLC, the taxotere was combined with DDP 90 mg/m2; for breast cancer, it was combined with ADM 40 mg/m2. The second treatment cycle was given after 3 weeks. At last 2 cycles were given. RESULTS: In 15 NSCLC patients, there were 6 PR, 7 NC and 2 PD. In 9 breast cancer patients, there were 2 CR, 6 PR and 1 NC. The major toxic reactions were neutropenia, diarrhea, fatigue, muscle pain and alopecia. Grade 3 and grade 4 neutropenia occurred in 9 and 4 cases, respectively. Decrease in hemoglobin and thrombocytopenia were mild. Diarrhea occurred in 19 cases and allergic reaction in 1 case. CONCLUSION: Taxotere is effective in the combined treatment of advanced NSCLC and breast cancer. The toxic reactions are tolerable.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11776652&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||